NEXT SCIENCE LIMITED - Announcements

Market Cap $109.3M Add to my watchlist

Healthcare Medical Instruments & Supplies

Next Science Limited is an Australia-based medical technology company. The Company’s... Next Science Limited is an Australia-based medical technology company. The Company’s primary focus is on the development and commercialization of its proprietary XBIO technology to reduce the impact of biofilm-based infections on human health. XBIO is a non-toxic technology with an efficacy in eradicating both biofilm-based and free-floating bacteria. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. BLASTX Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing.More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

NXS	Appendix 4C & Quarterly Activity Report - 31 March 2024	PRICE SENSITIVE	24/04/24	409.47KB	Share
NXS	Publication of Dr. Harris XPERIENCE study	PRICE SENSITIVE	18/04/24	170.21KB	Share
NXS	Preliminary results of further XPERIENCE studies released	PRICE SENSITIVE	17/04/24	172.43KB	Share
NXS	Study published showing impact of XPERIENCE on SSIs	PRICE SENSITIVE	16/04/24	168.16KB	Share
NXS	Publication of study showing BLASTX increases NPWT efficacy	PRICE SENSITIVE	09/04/24	185.13KB	Share
NXS	FY23 Annual Result Investor Presentation	PRICE SENSITIVE	28/02/24	1.02MB	Share
NXS	Next Science reports FY23 Result	PRICE SENSITIVE	28/02/24	186.4KB	Share
NXS	Appendix 4E / FY23 Financial Statements	PRICE SENSITIVE	28/02/24	1.14MB	Share
NXS	Appendix 4C & Quarterly Activity Report - 31 December 2023	PRICE SENSITIVE	30/01/24	324.86KB	Share
NXS	XPERIENCE study findings published	PRICE SENSITIVE	22/12/23	168.05KB	Share
NXS	Response to ASX Aware Letter	PRICE SENSITIVE	07/11/23	785.32KB	Share
NXS	XPERIENCE study findings released	PRICE SENSITIVE	03/11/23	179.47KB	Share
NXS	Investor Presentation - Q3 2023	PRICE SENSITIVE	23/10/23	618.81KB	Share
NXS	Quarterly Activity Report - 30 September 2023	PRICE SENSITIVE	23/10/23	176.67KB	Share
NXS	Appendix 4C - 30 September 2023	PRICE SENSITIVE	23/10/23	261.2KB	Share
NXS	Successful completion of Share Purchase Plan & US Offer	PRICE SENSITIVE	22/09/23	165.12KB	Share
NXS	Half Year Results & Capital Raise Presentation	PRICE SENSITIVE	31/08/23	2.29MB	Share
NXS	Half Year Report & Appendix 4D	PRICE SENSITIVE	31/08/23	557.76KB	Share
NXS	Half Year Results & Capital Raise Update	PRICE SENSITIVE	31/08/23	271.48KB	Share
NXS	Trading Halt	PRICE SENSITIVE	29/08/23	138.39KB	Share
NXS	Potential Anti-Inflammatory Benefit For XPERIENCE	PRICE SENSITIVE	09/08/23	194.97KB	Share
NXS	Investor Presentation	PRICE SENSITIVE	08/08/23	1.46MB	Share
NXS	Investor Presentation - Q2 2023	PRICE SENSITIVE	27/07/23	1.01MB	Share
NXS	Quarterly Activity Report - 30 June 2023	PRICE SENSITIVE	27/07/23	194.59KB	Share
NXS	Appendix 4C - 30 June 2023	PRICE SENSITIVE	27/07/23	216.77KB	Share
NXS	Market Update	PRICE SENSITIVE	29/06/23	163.51KB	Share
NXS	Appointment of new Managing Director and CEO	PRICE SENSITIVE	16/06/23	188.38KB	Share
NXS	Investor Presentation - Q1 2023	PRICE SENSITIVE	21/04/23	896.74KB	Share
NXS	Quarterly Activity Report - 31 March 2023	PRICE SENSITIVE	21/04/23	191.13KB	Share
NXS	Appendix 4C - 31 March 2023	PRICE SENSITIVE	21/04/23	360.2KB	Share
NXS	FY22 Investor Presentation	PRICE SENSITIVE	28/02/23	856.66KB	Share
NXS	Next Science FY22 Results and FY23 Outlook	PRICE SENSITIVE	28/02/23	158.9KB	Share
NXS	Appendix 4E / FY22 Financial Statements	PRICE SENSITIVE	28/02/23	1.1MB	Share
NXS	Appendix 4C - 31 December 2022	PRICE SENSITIVE	30/01/23	327.67KB	Share
NXS	Quarterly Activity Report - 31 December 2022	PRICE SENSITIVE	30/01/23	100.7KB	Share
NXS	Next Science secures A$10M convertible notes due 2024	PRICE SENSITIVE	13/12/22	179.31KB	Share
NXS	Quarterly Activity Report - 30 September 2022	PRICE SENSITIVE	28/10/22	165.29KB	Share
NXS	Appendix 4C - 30 September 2022	PRICE SENSITIVE	28/10/22	355.37KB	Share
NXS	Next Science US Medicare accreditation signals growth	PRICE SENSITIVE	19/10/22	117.17KB	Share
NXS	Trading Halt	PRICE SENSITIVE	18/10/22	116.23KB	Share
NXS	Pause in Trading	PRICE SENSITIVE	18/10/22	115.25KB	Share
NXS	Next Science's XPERIENCE product cleared for sale in Canada	PRICE SENSITIVE	26/08/22	90.2KB	Share
NXS	Half Year Results Investor Presentation	PRICE SENSITIVE	25/08/22	988.65KB	Share
NXS	Half Year Report & Appendix 4D	PRICE SENSITIVE	25/08/22	575.78KB	Share
NXS	Investor Presentation - Q2 2022	PRICE SENSITIVE	25/07/22	773.45KB	Share
NXS	Quarterly Activity Report - 30 June 2022	PRICE SENSITIVE	25/07/22	114.05KB	Share
NXS	Appendix 4C - 30 June 2022	PRICE SENSITIVE	25/07/22	347.33KB	Share
NXS	Next Science to strengthen senior leadership presence in US	PRICE SENSITIVE	27/05/22	87.24KB	Share
NXS	Oraderm Pharmaceuticals appointed as BlastX distributor	PRICE SENSITIVE	19/05/22	87.14KB	Share
NXS	Investor Presentation - Q1 2022	PRICE SENSITIVE	28/04/22	814.49KB	Share
NXS	Appendix 4C - 31 March 2022	PRICE SENSITIVE	28/04/22	352.97KB	Share
NXS	Quarterly Activity Report - 31 March 2022	PRICE SENSITIVE	28/04/22	149.38KB	Share
NXS	Next Science SPP Offer Opens	PRICE SENSITIVE	04/03/22	90.93KB	Share
NXS	Next Science raises A$10M and launches A$5M SPP	PRICE SENSITIVE	24/02/22	107.67KB	Share
NXS	Investor Presentation	PRICE SENSITIVE	23/02/22	592.27KB	Share
NXS	Appendix 4E / FY21 Financial Statements	PRICE SENSITIVE	23/02/22	959.05KB	Share
NXS	Trading Halt	PRICE SENSITIVE	23/02/22	118.12KB	Share
NXS	Investor Presentation - Q4 FY21	PRICE SENSITIVE	31/01/22	396.21KB	Share
NXS	Quarterly Activity Report - 31 December 2021	PRICE SENSITIVE	31/01/22	94.28KB	Share
NXS	Appendix 4C - 31 December 2021	PRICE SENSITIVE	31/01/22	267.3KB	Share
NXS	Enhanced sales & distribution relationship with Zimmer	PRICE SENSITIVE	31/01/22	90.69KB	Share
NXS	XPERIENCE cleared by TGA for sale in Australia	PRICE SENSITIVE	08/11/21	121.37KB	Share
NXS	Q3 FY21 Investor Presentation	PRICE SENSITIVE	01/11/21	1014.34KB	Share
NXS	Agreement signed with TELA Bio Inc	PRICE SENSITIVE	01/11/21	86.34KB	Share
NXS	Quarterly Activity Report & Appendix 4C - 30 September 2021	PRICE SENSITIVE	28/10/21	867.41KB	Share
NXS	Update on Irrimax complaint	PRICE SENSITIVE	30/08/21	79.99KB	Share
NXS	Half Year Results Investor Presentation	PRICE SENSITIVE	30/08/21	874.2KB	Share
NXS	Half Year Results	PRICE SENSITIVE	30/08/21	102.54KB	Share
NXS	Half Year Report & Appendix 4D	PRICE SENSITIVE	30/08/21	513KB	Share
NXS	Irrimax complaint	PRICE SENSITIVE	27/08/21	81.37KB	Share
NXS	Record revenue growth in 1H 2021	PRICE SENSITIVE	22/07/21	135.66KB	Share
NXS	Quarterly Activity Report - 30 June 2021	PRICE SENSITIVE	22/07/21	474.03KB	Share
NXS	Appendix 4C - 30 June 2021	PRICE SENSITIVE	22/07/21	225.36KB	Share
NXS	Zimmer complaint	PRICE SENSITIVE	24/06/21	81.1KB	Share
NXS	Update on expected revenue for H1	PRICE SENSITIVE	11/06/21	93.39KB	Share
NXS	BlastX approved by TGA for sale in Australia	PRICE SENSITIVE	27/05/21	164.2KB	Share
NXS	2021 AGM Presentation	PRICE SENSITIVE	05/05/21	1.56MB	Share
NXS	2021 AGM Chair & Managing Director Addresses	PRICE SENSITIVE	05/05/21	157.38KB	Share
NXS	XPerience No Rinse Antimicrobial Solution cleared by FDA	PRICE SENSITIVE	26/04/21	143.81KB	Share
NXS	Quarterly Activity Report - 31 March 2021	PRICE SENSITIVE	13/04/21	215.82KB	Share
NXS	Appendix 4C - 31 March 2021	PRICE SENSITIVE	13/04/21	238.05KB	Share
NXS	S&P DJI Announces March 2021 Quarterly Rebalance	PRICE SENSITIVE	12/03/21	183.24KB	Share
NXS	Investor Presentation	PRICE SENSITIVE	22/02/21	1.49MB	Share
NXS	Appendix 4E / FY20 Financial Statements	PRICE SENSITIVE	22/02/21	897.22KB	Share
NXS	Investor Presentation January 2021	PRICE SENSITIVE	28/01/21	763.8KB	Share
NXS	Quarterly Activity Report & Appendix 4C - 31 December 2020	PRICE SENSITIVE	28/01/21	410.56KB	Share
NXS	Next Science receives CE Mark approval for BlastX	PRICE SENSITIVE	21/12/20	207.28KB	Share
NXS	Non-renewal of 3M distribution agreement	PRICE SENSITIVE	23/11/20	126.73KB	Share
NXS	Managing Director's EGM Address	PRICE SENSITIVE	18/11/20	211.09KB	Share
NXS	Quarterly Activity Report & Appendix 4C - 30 Sept 2020	PRICE SENSITIVE	27/10/20	467.42KB	Share
NXS	Successful completion of Share Purchase Plan	PRICE SENSITIVE	14/10/20	129.88KB	Share
NXS	Next Science SPP Offer Opens	PRICE SENSITIVE	25/09/20	1.35MB	Share
NXS	Proposed issue of Securities - NXS	PRICE SENSITIVE	17/09/20	36.64KB	Share
NXS	Successful placement to support US launch of XPerience	PRICE SENSITIVE	17/09/20	153.28KB	Share
NXS	Capital raise to support launch of XPerience	PRICE SENSITIVE	16/09/20	200.11KB	Share
NXS	Trading Halt	PRICE SENSITIVE	16/09/20	115.35KB	Share
NXS	Pause in Trading	PRICE SENSITIVE	16/09/20	115.84KB	Share
NXS	Update on XPerience FDA approval process	PRICE SENSITIVE	07/09/20	128.29KB	Share
NXS	Managing Director's Address - Half Year Results	PRICE SENSITIVE	26/08/20	223.43KB	Share
NXS	Investor Presentation	PRICE SENSITIVE	26/08/20	1.6MB	Share

NXS Appendix 4C & Quarterly Activity Report - 31 March 2024
24/04/24	PRICE SENSITIVE	409.47KB	Share
NXS Publication of Dr. Harris XPERIENCE study
18/04/24	PRICE SENSITIVE	170.21KB	Share
NXS Preliminary results of further XPERIENCE studies released
17/04/24	PRICE SENSITIVE	172.43KB	Share
NXS Study published showing impact of XPERIENCE on SSIs
16/04/24	PRICE SENSITIVE	168.16KB	Share
NXS Publication of study showing BLASTX increases NPWT efficacy
09/04/24	PRICE SENSITIVE	185.13KB	Share
NXS FY23 Annual Result Investor Presentation
28/02/24	PRICE SENSITIVE	1.02MB	Share
NXS Next Science reports FY23 Result
28/02/24	PRICE SENSITIVE	186.4KB	Share
NXS Appendix 4E / FY23 Financial Statements
28/02/24	PRICE SENSITIVE	1.14MB	Share
NXS Appendix 4C & Quarterly Activity Report - 31 December 2023
30/01/24	PRICE SENSITIVE	324.86KB	Share
NXS XPERIENCE study findings published
22/12/23	PRICE SENSITIVE	168.05KB	Share
NXS Response to ASX Aware Letter
07/11/23	PRICE SENSITIVE	785.32KB	Share
NXS XPERIENCE study findings released
03/11/23	PRICE SENSITIVE	179.47KB	Share
NXS Investor Presentation - Q3 2023
23/10/23	PRICE SENSITIVE	618.81KB	Share
NXS Quarterly Activity Report - 30 September 2023
23/10/23	PRICE SENSITIVE	176.67KB	Share
NXS Appendix 4C - 30 September 2023
23/10/23	PRICE SENSITIVE	261.2KB	Share
NXS Successful completion of Share Purchase Plan & US Offer
22/09/23	PRICE SENSITIVE	165.12KB	Share
NXS Half Year Results & Capital Raise Presentation
31/08/23	PRICE SENSITIVE	2.29MB	Share
NXS Half Year Report & Appendix 4D
31/08/23	PRICE SENSITIVE	557.76KB	Share
NXS Half Year Results & Capital Raise Update
31/08/23	PRICE SENSITIVE	271.48KB	Share
NXS Trading Halt
29/08/23	PRICE SENSITIVE	138.39KB	Share
NXS Potential Anti-Inflammatory Benefit For XPERIENCE
09/08/23	PRICE SENSITIVE	194.97KB	Share
NXS Investor Presentation
08/08/23	PRICE SENSITIVE	1.46MB	Share
NXS Investor Presentation - Q2 2023
27/07/23	PRICE SENSITIVE	1.01MB	Share
NXS Quarterly Activity Report - 30 June 2023
27/07/23	PRICE SENSITIVE	194.59KB	Share
NXS Appendix 4C - 30 June 2023
27/07/23	PRICE SENSITIVE	216.77KB	Share
NXS Market Update
29/06/23	PRICE SENSITIVE	163.51KB	Share
NXS Appointment of new Managing Director and CEO
16/06/23	PRICE SENSITIVE	188.38KB	Share
NXS Investor Presentation - Q1 2023
21/04/23	PRICE SENSITIVE	896.74KB	Share
NXS Quarterly Activity Report - 31 March 2023
21/04/23	PRICE SENSITIVE	191.13KB	Share
NXS Appendix 4C - 31 March 2023
21/04/23	PRICE SENSITIVE	360.2KB	Share
NXS FY22 Investor Presentation
28/02/23	PRICE SENSITIVE	856.66KB	Share
NXS Next Science FY22 Results and FY23 Outlook
28/02/23	PRICE SENSITIVE	158.9KB	Share
NXS Appendix 4E / FY22 Financial Statements
28/02/23	PRICE SENSITIVE	1.1MB	Share
NXS Appendix 4C - 31 December 2022
30/01/23	PRICE SENSITIVE	327.67KB	Share
NXS Quarterly Activity Report - 31 December 2022
30/01/23	PRICE SENSITIVE	100.7KB	Share
NXS Next Science secures A$10M convertible notes due 2024
13/12/22	PRICE SENSITIVE	179.31KB	Share
NXS Quarterly Activity Report - 30 September 2022
28/10/22	PRICE SENSITIVE	165.29KB	Share
NXS Appendix 4C - 30 September 2022
28/10/22	PRICE SENSITIVE	355.37KB	Share
NXS Next Science US Medicare accreditation signals growth
19/10/22	PRICE SENSITIVE	117.17KB	Share
NXS Trading Halt
18/10/22	PRICE SENSITIVE	116.23KB	Share
NXS Pause in Trading
18/10/22	PRICE SENSITIVE	115.25KB	Share
NXS Next Science's XPERIENCE product cleared for sale in Canada
26/08/22	PRICE SENSITIVE	90.2KB	Share
NXS Half Year Results Investor Presentation
25/08/22	PRICE SENSITIVE	988.65KB	Share
NXS Half Year Report & Appendix 4D
25/08/22	PRICE SENSITIVE	575.78KB	Share
NXS Investor Presentation - Q2 2022
25/07/22	PRICE SENSITIVE	773.45KB	Share
NXS Quarterly Activity Report - 30 June 2022
25/07/22	PRICE SENSITIVE	114.05KB	Share
NXS Appendix 4C - 30 June 2022
25/07/22	PRICE SENSITIVE	347.33KB	Share
NXS Next Science to strengthen senior leadership presence in US
27/05/22	PRICE SENSITIVE	87.24KB	Share
NXS Oraderm Pharmaceuticals appointed as BlastX distributor
19/05/22	PRICE SENSITIVE	87.14KB	Share
NXS Investor Presentation - Q1 2022
28/04/22	PRICE SENSITIVE	814.49KB	Share
NXS Appendix 4C - 31 March 2022
28/04/22	PRICE SENSITIVE	352.97KB	Share
NXS Quarterly Activity Report - 31 March 2022
28/04/22	PRICE SENSITIVE	149.38KB	Share
NXS Next Science SPP Offer Opens
04/03/22	PRICE SENSITIVE	90.93KB	Share
NXS Next Science raises A$10M and launches A$5M SPP
24/02/22	PRICE SENSITIVE	107.67KB	Share
NXS Investor Presentation
23/02/22	PRICE SENSITIVE	592.27KB	Share
NXS Appendix 4E / FY21 Financial Statements
23/02/22	PRICE SENSITIVE	959.05KB	Share
NXS Trading Halt
23/02/22	PRICE SENSITIVE	118.12KB	Share
NXS Investor Presentation - Q4 FY21
31/01/22	PRICE SENSITIVE	396.21KB	Share
NXS Quarterly Activity Report - 31 December 2021
31/01/22	PRICE SENSITIVE	94.28KB	Share
NXS Appendix 4C - 31 December 2021
31/01/22	PRICE SENSITIVE	267.3KB	Share
NXS Enhanced sales & distribution relationship with Zimmer
31/01/22	PRICE SENSITIVE	90.69KB	Share
NXS XPERIENCE cleared by TGA for sale in Australia
08/11/21	PRICE SENSITIVE	121.37KB	Share
NXS Q3 FY21 Investor Presentation
01/11/21	PRICE SENSITIVE	1014.34KB	Share
NXS Agreement signed with TELA Bio Inc
01/11/21	PRICE SENSITIVE	86.34KB	Share
NXS Quarterly Activity Report & Appendix 4C - 30 September 2021
28/10/21	PRICE SENSITIVE	867.41KB	Share
NXS Update on Irrimax complaint
30/08/21	PRICE SENSITIVE	79.99KB	Share
NXS Half Year Results Investor Presentation
30/08/21	PRICE SENSITIVE	874.2KB	Share
NXS Half Year Results
30/08/21	PRICE SENSITIVE	102.54KB	Share
NXS Half Year Report & Appendix 4D
30/08/21	PRICE SENSITIVE	513KB	Share
NXS Irrimax complaint
27/08/21	PRICE SENSITIVE	81.37KB	Share
NXS Record revenue growth in 1H 2021
22/07/21	PRICE SENSITIVE	135.66KB	Share
NXS Quarterly Activity Report - 30 June 2021
22/07/21	PRICE SENSITIVE	474.03KB	Share
NXS Appendix 4C - 30 June 2021
22/07/21	PRICE SENSITIVE	225.36KB	Share
NXS Zimmer complaint
24/06/21	PRICE SENSITIVE	81.1KB	Share
NXS Update on expected revenue for H1
11/06/21	PRICE SENSITIVE	93.39KB	Share
NXS BlastX approved by TGA for sale in Australia
27/05/21	PRICE SENSITIVE	164.2KB	Share
NXS 2021 AGM Presentation
05/05/21	PRICE SENSITIVE	1.56MB	Share
NXS 2021 AGM Chair & Managing Director Addresses
05/05/21	PRICE SENSITIVE	157.38KB	Share
NXS XPerience No Rinse Antimicrobial Solution cleared by FDA
26/04/21	PRICE SENSITIVE	143.81KB	Share
NXS Quarterly Activity Report - 31 March 2021
13/04/21	PRICE SENSITIVE	215.82KB	Share
NXS Appendix 4C - 31 March 2021
13/04/21	PRICE SENSITIVE	238.05KB	Share
NXS S&P DJI Announces March 2021 Quarterly Rebalance
12/03/21	PRICE SENSITIVE	183.24KB	Share
NXS Investor Presentation
22/02/21	PRICE SENSITIVE	1.49MB	Share
NXS Appendix 4E / FY20 Financial Statements
22/02/21	PRICE SENSITIVE	897.22KB	Share
NXS Investor Presentation January 2021
28/01/21	PRICE SENSITIVE	763.8KB	Share
NXS Quarterly Activity Report & Appendix 4C - 31 December 2020
28/01/21	PRICE SENSITIVE	410.56KB	Share
NXS Next Science receives CE Mark approval for BlastX
21/12/20	PRICE SENSITIVE	207.28KB	Share
NXS Non-renewal of 3M distribution agreement
23/11/20	PRICE SENSITIVE	126.73KB	Share
NXS Managing Director's EGM Address
18/11/20	PRICE SENSITIVE	211.09KB	Share
NXS Quarterly Activity Report & Appendix 4C - 30 Sept 2020
27/10/20	PRICE SENSITIVE	467.42KB	Share
NXS Successful completion of Share Purchase Plan
14/10/20	PRICE SENSITIVE	129.88KB	Share
NXS Next Science SPP Offer Opens
25/09/20	PRICE SENSITIVE	1.35MB	Share
NXS Proposed issue of Securities - NXS
17/09/20	PRICE SENSITIVE	36.64KB	Share
NXS Successful placement to support US launch of XPerience
17/09/20	PRICE SENSITIVE	153.28KB	Share
NXS Capital raise to support launch of XPerience
16/09/20	PRICE SENSITIVE	200.11KB	Share
NXS Trading Halt
16/09/20	PRICE SENSITIVE	115.35KB	Share
NXS Pause in Trading
16/09/20	PRICE SENSITIVE	115.84KB	Share
NXS Update on XPerience FDA approval process
07/09/20	PRICE SENSITIVE	128.29KB	Share
NXS Managing Director's Address - Half Year Results
26/08/20	PRICE SENSITIVE	223.43KB	Share
NXS Investor Presentation
26/08/20	PRICE SENSITIVE	1.6MB	Share

REFRESH

1 2

(20min delay)
Last 37.5¢		Change -0.005(1.32%)		Mkt cap ! $109.3M

Open	High	Low	Value	Volume
38.5¢	38.5¢	37.5¢	$37.03K	97.17K

Buyers (Bids)

No.	Vol.	Price($)
1	10000	35.0¢

Sellers (Offers)

Price($)	Vol.	No.
38.5¢	33285	1

View Market Depth

No.	Vol.	Price($)
1	10000	0.350
1	14000	0.330
1	3076	0.325
1	62500	0.320
1	3175	0.315

Price($)	Vol.	No.
0.385	33285	1
0.390	55412	1
0.400	672	2
0.415	10000	1
0.420	28189	2

Last trade - 16.10pm 15/05/2024 (20 minute delay)


Last 37.5¢		Change -0.005 ( 0.00 %)
Open	High	Low	Volume
38.5¢	39.0¢	37.5¢	6130
Last updated 14.36pm 15/05/2024 ?

NXS (ASX) Chart

NEXT SCIENCE LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories